<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04084327</url>
  </required_header>
  <id_info>
    <org_study_id>acute b All</org_study_id>
    <nct_id>NCT04084327</nct_id>
  </id_info>
  <brief_title>Immunophenotyping of Acute b Cell Lymphoblstic Leukemia</brief_title>
  <official_title>Immunophenotyping of Acute b Cell Lymphoblastic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>South Egypt Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>South Egypt Cancer Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To study the immunophenotyping pattern of acute B lymphoblastic leukemia in south Egypt
      Cancer Institute iand its correlation with disease outcome
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      study the immunophenotyping pattern of acute B lymphoblastic leukemia in south Egypt Cancer
      Institute from 2009 -2019 and its correlation with disease outcome
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2019</start_date>
  <completion_date type="Anticipated">December 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>overall survival outcome</measure>
    <time_frame>10 years</time_frame>
    <description>overall survival outcome</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Disease-free survival outcome</measure>
    <time_frame>10 years</time_frame>
    <description>Disease-free survival outcome</description>
  </primary_outcome>
  <primary_outcome>
    <measure>association of novel CD markers with old markers for assessment of disease outcome</measure>
    <time_frame>10 years</time_frame>
    <description>association of novel CD markers with old markers for assessment of disease outcome</description>
  </primary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Acute Leukemia</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>stastical analysis</intervention_name>
    <description>1-Clinical examination data-Complete Blood Count (CBC).Bone Marrow Aspiration (BMA)-Bone Marrow Biopsy (BMB). (if available)-Immunophenotyping results (IPT).Cytogenetic results</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        new cases Who didn`t receive treatment.Age above 1 years old.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  New cases admitted to SECI Who didn`t receive treatment.Age above 1 years old.

        Exclusion Criteria:

          -  Cases who received treatment Patients below 1 years old.Patients diagnosed as AML or
             T-ALL
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Months</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <reference>
    <citation>Keegan A, Charest K, Schmidt R, Briggs D, Deangelo DJ, Li B, Morgan EA, Pozdnyakova O. Flow cytometric minimal residual disease assessment of peripheral blood in acute lymphoblastic leukaemia patients has potential for early detection of relapsed extramedullary disease. J Clin Pathol. 2018 Jul;71(7):653-658. doi: 10.1136/jclinpath-2017-204828. Epub 2018 Mar 27.</citation>
    <PMID>29588374</PMID>
  </reference>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>October 16, 2018</study_first_submitted>
  <study_first_submitted_qc>September 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 10, 2019</study_first_posted>
  <last_update_submitted>September 9, 2019</last_update_submitted>
  <last_update_submitted_qc>September 9, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>South Egypt Cancer Institute</investigator_affiliation>
    <investigator_full_name>ayat ahmed mohamed</investigator_full_name>
    <investigator_title>principle investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

